Tumor-on-a-chip model shows pancreatic cancer hijacks immune cells

A micro‑engineered “tumor‑on‑a‑chip” platform now allows researchers to observe in real time how pancreatic cancer cells enlist the body’s own immune cells to support tumor survival. The study, published in the journal *Biofabrication*, describes a microfluidic model that replicates the tumor microenvironment and captures the dynamic interactions between malignant pancreatic cells and recruited immune populations. Using live imaging and molecular analysis, the investigators identified specific signaling pathways through which the cancer cells co‑opt immune cells, creating a protective niche that promotes resistance to conventional therapies.

The findings highlight several molecular targets that could disrupt this immunological crosstalk, offering a potential strategy to weaken the tumor’s defenses and improve the efficacy of existing treatments. By providing a controllable, physiologically relevant system, the tumor‑on‑a‑chip model may accelerate the development of combination therapies aimed at both the cancer cells and their supportive immune environment, advancing efforts to combat one of the most lethal malignancies.